Thomas Stegmann on new blood vessel growth treatment
by Hylton Jolliffe
Malorye Branca interviews Thomas Stegmann, whose company - CardioVascular BioTherapeutics - has developed a novel medical therapy that encourages new blood vessel growth in damaged hearts that could, says Stegmann, prove safer and more cost-effective than traditional therapies. From the 4th Annual World Health Care Congress held in Washington DC in April.